TY - JOUR
T1 - Molecular biology of bone metastasis
AU - Kingsley, Lauren A.
AU - Fournier, Pierrick G.J.
AU - Chirgwin, John M.
AU - Guise, Theresa A.
PY - 2007/10/1
Y1 - 2007/10/1
N2 - Metastasis is a final stage of tumor progression. Breast and prostate cancer cells preferentially metastasize to bone, wherein they cause incurable osteolytic and osteoblastic lesions. The bone matrix is rich in factors, such as transforming growth factor-β and insulin-like growth factors, which are released into the tumor microenvironment by osteolysis. These factors stimulate the growth of tumor cells and alter their phenotype, thus promoting a vicious cycle of metastasis and bone pathology. Physical factors within the bone microenvironment, including low oxygen levels, acidic pH, and high extracellular calcium concentrations, may also enhance tumor growth. These elements of the microenvironment are potential targets for chemotherapeutic intervention to halt tumor growth and suppress bone metastasis.
AB - Metastasis is a final stage of tumor progression. Breast and prostate cancer cells preferentially metastasize to bone, wherein they cause incurable osteolytic and osteoblastic lesions. The bone matrix is rich in factors, such as transforming growth factor-β and insulin-like growth factors, which are released into the tumor microenvironment by osteolysis. These factors stimulate the growth of tumor cells and alter their phenotype, thus promoting a vicious cycle of metastasis and bone pathology. Physical factors within the bone microenvironment, including low oxygen levels, acidic pH, and high extracellular calcium concentrations, may also enhance tumor growth. These elements of the microenvironment are potential targets for chemotherapeutic intervention to halt tumor growth and suppress bone metastasis.
UR - http://www.scopus.com/inward/record.url?scp=35848970582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35848970582&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-07-0234
DO - 10.1158/1535-7163.MCT-07-0234
M3 - Review article
C2 - 17938257
AN - SCOPUS:35848970582
SN - 1535-7163
VL - 6
SP - 2609
EP - 2617
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 10
ER -